Related Experiment Video
Updated: Jan 15, 2026

Closure of a Patent Foramen Ovale PFO: An Intervention Sequence
Published on: December 23, 2022
What Caused an Acute Pontine Stroke in a Young Male Patient With a Patent Foramen Ovale?
Arpankumar Patel1, Umabalan Thirupathy2, Hanad Bashir3
1Internal Medicine, The Christ Hospital, Cincinnati, USA.
Insights
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a genetic condition often missed. Genetic testing confirmed CADASIL in a patient with stroke symptoms, highlighting its importance for early diagnosis.
Area of Science:
- Neurology
- Genetics
- Vascular Medicine
Background:
- Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a genetic cause of stroke and cognitive decline.
- It is frequently underdiagnosed, particularly in younger adults, due to its varied presentation.
- NOTCH3 gene mutations on chromosome 19 are the underlying cause of CADASIL.
Abstract:
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an important cause of stroke and cognitive decline in young adults due to a mutation in the NOTCH3 gene on chromosome 19 and is often underdiagnosed. We present to you a case of a middle-aged man who presents with acute stroke symptoms. He had a family history of recurrent transient ischemic attacks (TIAs) in his father and sister. Computed tomography (CT) of the head was negative, and magnetic resonance imaging (MRI) of the brain revealed an acute infarct involving the right pons and chronic small vessel ischemic changes. An echocardiogram showed a patent foramen ovale (PFO). It was then revealed that his sister had a questionable diagnosis of CADASIL disease. The patient's genetic testing revealed a positive monoallelic mutation of the NOTCH3 gene, confirming the diagnosis of CADASIL disease. CADASIL is a genetic disease that leads to acute stroke and dementia at a very young age and can often go undiagnosed in clinical practice. Recent advancements in molecular genetics and early recognition of this condition with genetic testing might help in risk stratification and preventing adverse cerebrovascular outcomes.

